STP 1
Alternative Names: STALICLA Therapeutic Package 1; STP-1Latest Information Update: 03 Jul 2024
At a glance
- Originator STALICLA
- Class Behavioural disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Phosphoric diester hydrolase inhibitors; Sodium-potassium-chloride symporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pervasive child development disorders
Most Recent Events
- 27 Jun 2024 Efficacy and adverse event data from the phase Ib trial in Pervasive child development disorders released bySTALICLA
- 17 Apr 2024 STP 1 is still in phase I trials for Pervasive child development disorders (STALICLA pipeline, April 2024)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Pervasive-child-development-disorders in USA (PO, Capsule)